Amneal PharmaceuticalsNYSE: AMRX

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the Company's total number of commercial injectable products available for the U.S. institutional market to over 40. The growth of Amneal's broad injectables portfolio will help address shortages of critical products where there may be l.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) Q1 2024 Earnings Conference Call is scheduled for May 3, 2024 at 8:30 AM ET. Company representatives include Tony DiMeo, Chirag Patel, Chintu Patel, Tasos Konidaris, and Joe Renda. Conference call participants include Nathan Rich, Leszek Sulewski, David Amsellem, Balaji Prasad, and Chris Schott. Good morning and thank you for joining the Amneal Pharmaceuticals First Quarter 2024 Earnings Call.

Amneal Pharmaceuticals announced on Friday that they had agreed to a settlement worth over $270 million to address allegations that they contributed to the devastating opioid epidemic in the United States, joining other pharmaceutical companies in resolving lawsuits related to the addiction crisis filed by states and local governments.

While the revenue and EPS figures for Amneal (AMRX) provide insight into its performance in the first quarter of 2024, it may be beneficial to also analyze how certain key metrics stack up against Wall Street forecasts and the previous year's figures.

Amneal Pharmaceuticals (AMRX) reported quarterly earnings of $0.14 per share, surpassing the Zacks Consensus Estimate of $0.09 per share. This is an improvement from earnings of $0.12 per share in the same quarter last year.

California's Democratic Governor announced Monday that the state will start selling its own generic version of Narcan, the drug that can help save a life in case of an opioid overdose.

Amneal's stock experienced a significant increase in the last trading session, accompanied by above-average trading volume. However, the recent changes in earnings estimates may not necessarily lead to additional price growth in the short term.

Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

The headline numbers for Amneal (AMRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.